Tim has extensive experience in the life sciences area relating to patent litigation and also non-contentious work on the creation and exploitation of intellectual property rights.
Tim is a partner in our Intellectual Property Group based in London.
Tim has a particular interest in the pharmaceutical and biotechnology sectors. He regularly provides advice on IP disputes with an international element, often co-ordinating with US clients and advisors, and running pan-European patent actions across a number of jurisdictions. Tim also provides commercial advice on the development, protection and exploitation of IP.
Recent reported UK decisions include: Positec v Husqvarna  EWHC 1061 (Pat) (robotic lawnmowers), Napp v Dr Reddy's  EWCA Civ 1053 (buprenorphine patches – Court of Appeal), Actavis v Boehringer Ingelheim C-577/13 (telmisartan/hydrochlorothiazide SPC - CJEU). Other patent disputes that Tim has advised on include Synthon v Forty Seven (immunoncology), Allergan v Ipsen (second medical use of Botox®), Uni-Pixel v CIT (touch screen technology) and Kingston v SanDisk (USBs).
Tim regularly speaks about intellectual property issues to an international audience, including at the Technology Transfer Summit in 2016 (Medellin) and 2017 (Santigao) and Life Sciences IP Minds Conference 2017 (London). In 2017 he contributed to teaching IP at The Oxford Said Business School, an IP summer school at Cambridge University and a Post Graduate IP Diploma at Oxford University.
Tim has a first class Chemistry degree from Oxford and was recognised as a "next generation" lawyer in the field of Pharmaceuticals and Biotechnology by the Legal 500. He is a member of the European Patent Lawyers Association (EPLAW) and American Intellectual Property Lawyers Association (AIPLA).